ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0451

Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 23-year Study

Jens Rathmann1, Mårten Segelmark2, Martin Englund3 and Aladdin Mohammad4, 1Rheumatology, Department of Clinical Sciences, Lund University, Lund, Skane Lan, Sweden, 2Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, 3Lund University, Lund, Sweden, 4Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden

Meeting: ACR Convergence 2022

Keywords: ANCA associated vasculitis, Epidemiology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Epidemiologic studies in ANCA associated vasculitis (AAV) have demonstrated geographical variation between different countries as well as increasing incidence and prevalence during the last 30 years. Some of these differences can be attributed to genetic and environmental factors, however different methodology for case-identification, increased physician awareness and improved survival might also influence results. We earlier described an incidence rate of 20.9/million inhabitants (1) and a point prevalence of 299/million for AAV in the same study area in 2003 (2). In this study we aim to update the epidemiology of AAV in a defined geographic area in southern Sweden using same case ascertainment and classification.

Methods: For the incidence estimation, the study area comprises 14 municipalities in southern Sweden with a total adult population (≥ 18 years) of 623 872 in 2019. All cases diagnosed with AAV from 1997 to 2019 in the study area were included in this study. Diagnosis of AAV was verified by case record review and cases were classified using EMA-algorithm. To study the point prevalence (p.p.), we included cases from 10 out of the 14 municipalities used in incidence estimates (Pop. 273135), to assure better comparability with previous p.p. results. The date of p.p. was January 1, 2020. Age and sex- specific incidence rates were estimated and the variation in incidence rate according to seasons was studied.

Results: Three hundred and seventy-four patients (47% female) were diagnosed with new onset AAV during study period. 192 patients were classified as GPA, 159 as MPA and 23 as EGPA. The median age at diagnosis was 67.5 (IQR 55—77) years. The average annual incidence rate per million adults was 30.1 (95%CI: 27.0, 33.1) for AAV, 15.4 (95%CI: 13.3, 17.6) for GPA, 12.8 (95%CI: 10.8, 14.8) for MPA and 1.8 (95%CI: 1.1, 2.6) for EGPA. Incidence rate is increasing with age. Age-specific incidence rates for MPA and MPO-positive disease are highest in patients aged 85 and older, whereas overall AAV, GPA and PR3 positive disease show peak incidence rates in patients between 70-84 years and decrease in older age. Incidence rates are highest in spring (IR 1.375, winter reference). At date of p.p. 117 patients were alive in the study area resulting in a p.p. of 428 per million adults. The prevalence was higher in men compared to women.

Conclusion: The incidence of AAV is increasing with older age reaching highest rate among people in age group 70-84 years. Annual incidence rates were stable during the study period. The prevalence of AAV has increased during the study period and is higher in men.

References:
1. Mohammad AJ, Rheumatology (Oxford). 2009;48(12):1560-5.
2. Mohammad AJ, et al. Rheumatology (Oxford) 2007;46:1329-37.

Supporting image 1

AAV: ANCA-associated vasculitis, GPA: granulomatosis with polyangiitis, MPA: microscopic polyangiitis, EGPA: eosinophilic granulomatosis with polyangiitis, PR3: proteinase_3, MPO: myeloperoxidase, 95% CI: 95% confidence-interval. *The study area for prevalence estimates comprises 10/14 (total population 2020: 273135) municipalities for better comparability to earlier studies in this cohort.


Disclosures: J. Rathmann, None; M. Segelmark, None; M. Englund, None; A. Mohammad, None.

To cite this abstract in AMA style:

Rathmann J, Segelmark M, Englund M, Mohammad A. Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 23-year Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/incidence-and-prevalence-of-anca-associated-vasculitis-in-southern-sweden-a-23-year-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-prevalence-of-anca-associated-vasculitis-in-southern-sweden-a-23-year-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology